A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Triple Negative Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Gilead Sciences
- Last updated on ClinicalTrials.gov
- January 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Los Angeles Cancer Network (LACN) - Good Sam · Los Angeles, CA
Georgia · 1
- Winship Cancer Institute - Emory University · Atlanta, GA
Kansas · 1
- The University of Kansas Hospital · Westwood, KS
Missouri · 1
- Siteman Cancer Center · St Louis, MO
Tennessee · 3
- West Cancer Centre · Germantown, TN
- SCRI Oncology Partners · Nashville, TN
- Tennessee Oncology, PLLC · Nashville, TN
Texas · 1
- Texas Oncology - DFW · Dallas, TX
Virginia · 1
- Virginia Oncology Associates · Norfolk, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.